In-Vitro Lung Model Global Market Report 2024

The in vitro lung model market size has grown exponentially in recent years. It will grow from $0.37 billion in 2023 to $0.44 billion in 2024 at a compound annual growth rate (CAGR) of 21%. The expansion observed during the historical period can be credited to several factors, including the rising incidence of respiratory ailments, heightened attention to personalized medicine, increased exploration of drug repurposing, a focus on precision medicine methodologies, and heightened recognition of environmental health hazards.

The vitro lung model market size is expected to see exponential growth in the next few years. It will grow to $0.96 billion in 2028 at a compound annual growth rate (CAGR) of 21.1%. The anticipated growth in the forecast period can be linked to various factors, notably the demand for drug development, the escalation in preclinical testing, heightened awareness regarding respiratory toxicology, a concentrated effort on regenerative medicine, escalating environmental apprehensions, and the rising population of older adults. Key trends expected in the forecast period encompass heightened demand for drug testing, advancements in 3D printing and organ-on-chip technologies, the integration of AI and machine learning, incorporation of sensors and monitoring apparatuses, diversification of applications beyond pharmaceuticals, and the formulation of disease-specific models.

The surge in clinical studies is anticipated to drive growth in the in vitro lung model market in the future. Clinical trials are investigations that evaluate the effectiveness of new medical approaches in human subjects. This increase in clinical studies is propelled by the growing demand for advanced medical treatments, rising healthcare needs, and the search for innovative solutions to complex health challenges. In vitro lung models play a crucial role in clinical trials by providing a controlled setting to examine how substances affect lung tissue, aiding in drug testing, assessing toxicity, modeling diseases, and understanding disease mechanisms. For instance, according to ClinicalTrials.gov, a US-based clinical trial registry, as of January 2024, there were 477,230 registered clinical trials globally, up from 437,508 in 2022. Consequently, the rise in clinical studies stimulates the in vitro lung model market.

Key players in the in vitro lung model market are developing 3D respiratory tissue models to enhance the physiological relevance and complexity of their models. These models are created by culturing selected respiratory cells in a specialized environment, allowing them to form a three-dimensional structure that mimics the function and morphology of the respiratory system. This provides a more physiologically relevant platform for research and drug testing. For example, in April 2023, MatTek Corporation, a US-based biotechnology company, launched EpiNasal, an innovative 3D respiratory tissue model made from primary human nasal epithelial cells. EpiNasal replicates the three-dimensional structure and functionality of nasal epithelium, including mucus-producing goblet cells, functional tight junctions, and beating cilia. The introduction of EpiNasal expands MatTek's range of 3D respiratory tissue models, offering a comprehensive system for studying the effects of pharmaceuticals, chemicals, pathogens, and consumer products on the human respiratory system.

In March 2021, CELLINK, a US-based bioconvergence company, acquired MatTek Corporation for an undisclosed sum. Through this acquisition, CELLINK aims to merge its expertise in lab-engineered human tissue with bioprinting technology to pioneer alternative test models, thereby reducing reliance on animal testing. This aligns with their vision of revolutionizing medicine through accurate, ethical testing and expanding scientific impact. MatTek Corporation is a US-based biotechnology company specializing in in vitro human tissue model innovation as a reliable alternative to animal testing.

Major companies operating in the in-vitro lung model market are Thermo Fisher Scientific Inc., Lonza Group AG, PerkinElmer Inc., Charles River Laboratories International Inc., Varian Medical Systems Inc., Epithelix, The Charles Stark Draper Laboratory Inc., STEMCELL Technologies, American Type Culture Collection (ATCC), BioIVT, InSphero, Emulate Inc., PhoenixBio Co. Ltd., Newcells Biotech, CN Bio Innovations Ltd., Mimetas, Cyfuse Biomedical K.K., 3D Biotek LLC, AlveoliX AG, AxoSim Technologies LLC, Elveflow, Hesperos Inc., Kugelmeiers Ag, SynVivo Inc., VITROCELL Systems GmbH.

North America was the largest region in the in-vitro lung model market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in-vitro lung model market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the in-vitro lung model market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

An in vitro lung model is a scientific construct devised to replicate the cellular, structural, and functional characteristics of the human lung within a controlled laboratory setting. These models empower researchers to explore disease progression, identify biomarkers, and evaluate treatment effectiveness. They serve as invaluable instruments for advancing our comprehension of lung biology, refining therapeutic approaches, and enhancing health outcomes.

The primary classifications of in vitro lung models include two-dimensional (2D) models and three-dimensional (3D) models. A 2D model presents a simplified depiction of lung cells and tissue on a flat surface, employed in fundamental research and preliminary substance testing. They find utility across various domains such as drug discovery, toxicology assessments, physiological investigations, as well as the advancement of three-dimensional (3D) model methodologies. These models are utilized by academic research institutions, pharmaceutical and biotechnology firms, among others.

The in vitro lung model market research report is one of a series of new reports that provides in vitro lung model market statistics, including the in vitro lung model industry global market size, regional shares, competitors with in vitro lung model market share, detailed in vitro lung model market segments, market trends, and opportunities, and any further data you may need to thrive in the in vitro lung model industry. These in vitro lung model market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The in-vitro lung model market consists of revenue earned by providing services such as customization services, training and education services, medical education, healthcare training, forensic science, repair and maintenance services, and consulting services. The market value includes the value of related goods sold by the service provider or included within the service offering. The In-vitro lung model models market also includes sales of anatomical organ models, muscle models, human skeleton models, anatomical charts, and posters. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.